<DOC>
	<DOCNO>NCT02922946</DOCNO>
	<brief_summary>The objective study evaluate effect time moderate-fat meal single dose pharmacokinetics entinostat evaluate safety tolerability entinostat feed fasting condition healthy adult subject .</brief_summary>
	<brief_title>Study Determine Effect Timing Meal Pharmacokinetics Entinostat</brief_title>
	<detailed_description>This 2-stage food effect ( time meal ) study . A total 48 subject dose Stage 2 conduct . Stage 1 conduct open-label , randomize , 2-way crossover study . On Day 1 period , subject receive single , oral dose entinostat fast feed condition . If preliminary result Stage 1 indicate timing meal exhibit significant effect bioavailability entinostat , Stage 2 conduct investigate effect meal either dose entinostat entinostat PK . Stage 2 conduct open-label , randomize , 3-way crossover study . On Day 1 period , subject receive single , oral dose entinostat fast feed condition .</detailed_description>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>Healthy adult 1955 year age screening . Continuous nonsmoker use nicotinecontaining product least 3 month prior first dose throughout study . Body mass index ≥ 18.5 screening . Medically healthy significant medical history , physical examination , laboratory value , vital sign , ECGs . Liver function test serum bilirubin must ≤ upper limit normal . Platelets , hemoglobin , hematocrit must &gt; low limit normal screening . Females nonchildbearing potential must undergo sterilization procedure note protocol least 6 month prior dose . Nonvasectomized male subject must agree use condom spermicide abstain sexual intercourse study 90 day beyond dose study drug . Male subject must agree donate sperm first dose 90 day beyond dose study drug . Understands study procedure inform consent form willing able comply protocol . Mentally legally incapacitate significant emotional problem screen expect conduct study . History presence clinically significant medical psychiatric condition disease opinion PI designee . History illness might confound result study pose additional risk subject participation study opinion PI designee . History presence alcoholism drug abuse within past 2 year prior dose . History presence clinically significant cancer , cardiovascular disorder , acute chronic gastrointestinal condition opinion PI . Females childbearing potential . Females positive pregnancy test lactating . Positive urine drug alcohol result screen checkin . Positive urine cotinine screening . Positive result screen HIV , hepatitis B surface antigen , hepatitis C virus Seated blood pressure le 90/40 mmHg great 140/90 mmHg screening . Seated heart rate lower 40 bpm high 99 bpm screening . QTcB interval ( correction value interval Q T wave ECG trace use Bazett Correction Formula ) &gt; 460 msec male &gt; 480 msec female ECG finding deem abnormal PI designee . Estimated creatinine clearance &lt; 90 mL/min screening . Unable refrain anticipates use prescription nonprescription medication drug know significant inhibitor CYP ( Cytochromes 450 ) enzyme and/or Pgp . Has diet incompatible onstudy diet within 28 day prior dose throughout study opinion PI designee . Is lactose intolerant . Donation blood significant blood loss within 56 day prior dose . Plasma donation within 7 day prior dose . Participation another clinical study 28 day prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>entinostat</keyword>
	<keyword>Histone Deacetylase Inhibitor</keyword>
	<keyword>HDAC</keyword>
</DOC>